Canadian Perspective on Overall survival (OS) in KATE2.

Watch Now Canadian Perspective on Overall survival (OS) in KATE2.

KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Watch Now KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Message from our Editor-in-Chief

Watch Now Message from our Editor-in-Chief

Message from our Scientific Editor

Watch Now Message from our Scientific Editor

Identifying Research Priorities in Prediction of Response in Patients with Early Breast Cancer

Watch Now Identifying Research Priorities in Prediction of Response in Patients with Early Breast Cancer